ArticleiScience2019
Lactococcus Lactis Subsp. cremoris Is an Efficacious Beneficial Bacterium that Limits Tissue Injury in the Intestine.
Article in iScience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 50 citations in OpenAlex.
- Article
- The effects of different forms of vitamin E on gut microbiota, mechanisms, and implications in disease prevention.The Journal of nutritional biochemistry · 2026Review
- Lactococcus cremoris decreases virulence‑associated properties, and modifies the protein profile of foodborne pathogen Campylobacter jejuni in biofilm.Gut pathogens · 2026Article
- Modulation of Gut Microbiota and Antibiotic Resistance Genes by Heat-KilledBioengineering (Basel, Switzerland) · 2025Article
- Composite Probiotics Improve Gut Health and Enhance Tryptophan Metabolism in Nursery Piglets During Liquid Feeding.International journal of molecular sciences · 2025Article
- Microbial Changes Occurring During Oronasal Fistula Wound Healing.Microorganisms · 2025Article
- Combining vitamin E metabolite 13'-carboxychromanol and a lactic acid bacterium synergistically mitigates colitis and colitis-associated dysbiosis in mice.Free radical biology & medicine · 2025Article
- Prebiotic inulin enhances gut microbial metabolism and anti-inflammation in apolipoprotein E4 mice with sex-specific implications.Scientific reports · 2023Article
- The Water Extract ofAntioxidants (Basel, Switzerland) · 2023Article
- Butyrate supplementation to pregnant mice elicits cytoprotection against colonic injury in the offspring.Pediatric research · 2022Article
- Prolonged Lifespan, Improved Perception, and Enhanced Host Defense of Caenorhabditis elegans by Lactococcus cremoris subsp.Microbiology spectrum · 2022Article
- Antioxidant potential of Pediococcus pentosaceus strains from the sow milk bacterial collection in weaned piglets.Microbiome · 2022Article
- The Gut-Brain Axis: Two Ways Signaling in Parkinson's Disease.Cellular and molecular neurobiology · 2022Review
- Review
- Pretreatment with IPA ameliorates colitis in mice: Colon transcriptome and fecal 16S amplicon profiling.Frontiers in immunology · 2022Article
- The emerging role of probiotics in neurodegenerative diseases: new hope for Parkinson's disease?Neural regeneration research · 2021Article
- Roles of the Polyphenol-Gut Microbiota Interaction in Alleviating Colitis and Preventing Colitis-Associated Colorectal Cancer.Advances in nutrition (Bethesda, Md.) · 2021Review
- Gut and Brain: Investigating Physiological and Pathological Interactions Between Microbiota and Brain to Gain New Therapeutic Avenues for Brain Diseases.Frontiers in neuroscience · 2021Review
- Predicting death by the loss of intestinal function.PloS one · 2020Article
- Probiotics for Parkinson's Disease.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
The use of beneficial bacteria to promote health is widely practiced. However, experimental evidence corroborating the efficacy of bacteria promoted with such claims remains limited. We address this gap by identifying a beneficial bacterium that protects against tissue damage and injury-induced inflammation in the gut. We first employed the Drosophila animal model to screen for the capacity of candidate beneficial bacteria to protect the fly gut against injury. From this screen, we identified Lactococcus lactis subsp. cremoris as a bacterium that elicited potent cytoprotective activity. Then, in a murine model, we demonstrated that the same strain confers powerful cytoprotective influences against radiological damage, as well as anti-inflammatory activity in a gut colitis model. In summary, we demonstrate the positive salutary effects of a beneficial bacterium, namely, L. lactis subsp. cremoris on intestinal tissue and propose the use of this strain as a therapeutic to promote intestinal health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.